Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
With
Merck Sharp & Dohme LLC
This study will assess the safety and tolerability of AMG 330 in combination with pembrolizumab and whether pembrolizumab will enhance the anti-AML activity of AMG 330. Both cohort 1 and 2 will include AMG 330 and pembrolizumab with the difference being the initiation date for pembrolizumab treatment.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
AML as defined by the WHO Classification persisting or recurring following one or more treatment courses. Except APL
Eastern Cooperative Oncology Group (ECOG) ≤1
You may not be if
Active extramedullary AML in the central nervous system.
Known hypersensitivity to immunoglobulins.
Non-manageable graft versus host disease.
Clareo Health | Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
